Zhijing Finance and Economics APP news, Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH) announced that the company has signed a "Pharmaceutical Technology License and Development Agreement" with Beijing Jia CoSi New Drug R&D Co., Ltd. ("Jia CoSi"). According to the agreement, Jia CoSi grants the company the exclusive license for the research, development, production, registration, and commercialization of the KRAS G12C inhibitor Gordalese and the SHP2 inhibitor JAB-3312 in China. The company will pay Jia CoSi a down payment of 0.15 billion yuan for this authorization, up to 0.7 billion yuan for development and sales milestone payments, and a double-digit percentage of sales commission, including value-added tax.

It is reported that Gordalese (JAB-21822) is a KRAS G12C inhibitor independently developed by Jia CoSi, mainly used for the treatment of advanced solid tumor patients with KRAS G12C mutation. JAB-3312 is a highly selective SHP2 inhibitor with the best potential in its class. This cooperation with Jia CoSi is highly aligned with the company's global strategy, further expanding the company's R&D pipeline in the field of oncology, including lung cancer, pancreatic cancer, and colorectal cancer, helping the company to build a product matrix for cancer treatment.